title: Locking the door to HIV entry: how far can we go?
authors.forename: Suzanne M
authors.initials: SM
authors.lastname: Crowe
authors.forename: Birgitta
authors.initials: B
authors.lastname: Asjo
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015704:CD4 Antigens / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000821:virology; D015658:HIV Infections / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D009000:Monocytes / Q000187:drug effects / Q000276:immunology / Q000821:virology; D014779:Virus Replication / Q000187:drug effects
chemical_list: D019380:Anti-HIV Agents; D000911:Antibodies, Monoclonal; D015704:CD4 Antigens